Aim: The brain region that shows reductions in regional cerebral blood flow (rCBF) earliest is the posterior cingulate cortex (PCC), which is thought to have a relationship with cognitive function. We made a hypothesis that the PCC hypoperfusion is a result of cholinergic dysfunction and can be restored by cholinergic enhancement. This present longitudinal study aimed to detect the restoration of PCC rCBF in response to donepezil, an acetylcholine esterase inhibitor.
Introduction
The posterior cingulate cortex (PCC) is of particular interest, because it has dense structural connections to many other brain regions and could serve as a hub, and it is metabolically active with high regional cerebral blood flow (rCBF) in healthy individuals. [1] [2] [3] The region is thought to play an important role in cognition, although consensus about the nature of its role has not been reached. 4 Reductions in rCBF and in the regional cerebral metabolic rate of glucose (rCMR glc ) in the PCC comprise the earliest signs of Alzheimer's disease (AD). 5, 6 The mechanism of rCBF reduction in PCC is not still established. We made a hypothesis that decreased PCC rCBF is due to integration of cholinergic dysfunction, and is related to the impaired learning and memory associated with early AD.
If the PCC is indeed associated with the symptoms of AD, rCBF in the area should be restored with the use of an acetylcholine esterase inhibitor, such as donepezil. However, previous longitudinal single-photon emission computed tomography (SPECT) studies where donepezil has been administered have not shown an increase in PCC rCBF (Table 1) . [7] [8] [9] [10] [11] [12] [13] [14] The present SPECT follow-up study aimed to determine whether PCC rCBF increases in response to donepezil and if so, to identify the optimal conditions for this to occur. As the PCC is one of the most vulnerable regions in AD and it is affected early during the course of the disease, we did not expect an increase in rCBF in this 
Methods

Patient selection
We carried out a prospective study. 16 Scores on the MMSE, which is used to screen for dementia, ranged from 21 to 26 (mean 23.6). None of the patients used tranquilizers, anti-anxiety agents or antidepressants that would affect the central nervous system. The patients were given donepezil orally (3 mg/day for 2 weeks, followed by 5 mg/day for 18 months). All patients tolerated the higher dose without serious adverse reactions, and cohabiting family members confirmed their compliance. The MMSE and the Japanese version of the AD assessment scalecognitive scale (ADAS-Jcog) were assessed at baseline, and at 6 and 18 months later. The patients were allocated to responder or non-responder subgroups based on an increase of ≥1 or a decrease of ≥0 compared with baseline MMSE scores at 6 months after therapy. According to Doody et al., the mean annual change in the MMSE scores of patients with untreated AD is À3.7 ± 4.6 (mean ± SD). 17 As an annual MMSE score change of 0.9 (mean + SD) as a cut-off was adequate, half of this value seemed suitable for an interval of 6 months. However, we selected a score of 1 as a cut-off for changes in MMSE scores, because the scores change by 1 point. We also included nine agematched healthy controls defined as being free of cognitive complaints, and having a clinical dementia rating (CDR) of 0 and MMSE scores ≥28.
Brain perfusion SPECT imaging
Resting patients with closed eyes and unplugged ears were assessed using N-isopropyl-p-[ ) and scatter was corrected with the triple energy window method.
Image analyses
Three-dimensional stereotactic surface projections (3D-SSP) created with Neurological Statistical Image Analysis Software (NEUROSTAT) developed by Minoshima et al. were applied to the 123 I-IMP SPECT images to generate Z-score maps.
18 Two-sample t-test values compared on a pixel-by-pixel basis between healthy controls and responders or non-responders (at baseline, and at 6 and 18 months) were transformed into Z-scores by probability integral transformation using NEUROSTAT. The rCBF distribution at baseline between the responders and the non-responders was compared. Statistical maps of changes in rCBF between values at baseline and at 6 months were also generated.
We applied region of interest (ROI) analysis to measure PCC rCBF together with the adjacent precuneus and in the anterior cingulate cortex (ACC) using stereotaxic extraction estimation (SEE; version 2.1) software (Nihon Mediphysics, Tokyo, Japan). 19 The precuneus and the ACC were selected as reference regions, because they are closely connected with PCC, and are less vulnerable than the PCC in mild AD in terms of rCBF decrease. The mean rCBF in each segment was automatically measured after segmentation based on anatomical classification of the standard brain (Fig. S1 ). We selected segments of the PCC (BA23 and BA31) and ACC (BA24) using Brodmann's area (BA) level. 19, 20 We defined the boundary of the precuneus using gyrus level instead of BA7, considering that the precuneus is the mesial extent of BA7, which also contains several other regions. Relative CBF 7, 9, 12 was determined by dividing the accumulation in each segment by global mean.
Statistical analysis
We used a one-way ANOVA to assess mean age and years of education among three groups. We applied the TukeyKramer test to correct the multiple comparison findings of changes in MMSE and ADAS-Jcog scores. Changes in relative CBF between baseline and 6 months were calculated using a paired t-test, with the Bonferroni correction. Correlations between rCBF changes in each segment and changes in MMSE or ADAS-Jcog scores were analyzed using the Pearson product-moment correlation coefficient. Table 2 compares the demographic features of the patients with mild AD and healthy controls. Age and years of education did not significantly differ among the three groups.
Results
Demographic characteristics
The MMSE scores at baseline also did not significantly differ among responders, non-responders and healthy controls. Mean MMSE and ADAS-Jcog scores were significantly improved at 6 months after baseline in the responders (P < 0.05), but deteriorated at 18 months.
The decline in mean MMSE and ADAS-Jcog scores between baseline and 18 months was consistent in the non-responders (Fig. S2) .
The rCBF distribution at baseline was not significantly different between the responders and the non-responders (Fig. S3) .
Changes in rCBF between baseline and 6 months later in patients with mild AD
We compared relative CBF in the bilateral PCC (BA23 and BA31), precuneus, and ACC (BA24) in segments of 3D brain images acquired at baseline and 6 months later from all patients (Table 3) . Regional CBF was elevated in the left BA23 and bilateral BA31 (P < 0.01) and in the right BA23 (P < 0.05).
Statistical maps of responders compared with healthy controls
A comparison of rCBF on 3D-SSP images between responders and healthy controls showed relative hypoperfusion in the bilateral PCC, precuneus, right parietal lobe and left orbitofrontal cortex at baseline in the responders (Fig. 1) . This distribution of decreased rCBF was typical of mild AD. Six months 
Statistical maps of non-responders compared with healthy controls
Comparisons of rCBF on 3D-SSP images from nonresponders and healthy controls showed relative hypoperfusion in the bilateral PCC, precuneus, parietal lobe and temporal lobe at baseline of non-responders (Fig. 1) . These findings became more remarkable at 18 months later.
Statistical maps of rCBF changes between baseline and 6 months in responders
Surface images of relative changes in rCBF between baseline and 6 months showed increased rCBF in the bilateral PCC, precuneus, ACC, thalamus and right dorsolateral prefrontal cortex of responders with mild AD (Fig. S4a ). There was a significant increase in rCBF in the rostral region of the bilateral PCC. Peak Z was observed in the PCC (Talairach coordinates: x = À4; y= À30; z = 34; Z-score, 4.36; Fig. S4b ).
Statistical maps of rCBF changes between baseline and 6 months in non-responders
Surface images of relative changes in rCBF between baseline and 6 months showed increased rCBF in the bilateral ACC, thalamus and right dorsolateral prefrontal cortex of non-responders with mild AD (Fig. S4c) . The rCBF did not significantly increase (Fig. S4d) .
Correlations between changes in rCBF and in MMSE and ADAS-Jcog scores in responders after 6 months of donepezil therapy Table 4 shows that the rCBF in bilateral PCC (BA31) significantly correlated with MMSE and ADAS-Jcog scores (P < 0.01). The rCBF in the left PCC (BA23) and right ACC significantly correlated with MMSE scores, and those in the left PCC (BA23) and bilateral ACC correlated with ADAS-Jcog scores (P < 0.05).
Discussion
The present SPECT follow-up study successfully showed that rCBF increased transiently in the PCC of patients with AD who had relatively high baseline MMSE scores and cognitive improvement (responders). Statistical maps between baseline and 6 months showed obvious rCBF restoration mainly in the bilateral rostral part of the PCC, which Figure 1 Statistical maps of regional cerebral blood flow in responders and non-responders compared with healthy controls at baseline,correlated with improvements in cognitive function. Statistical maps of responders compared with normal individuals showed a typical decrease in the rCBF associated with AD at baseline and at 18 months. These findings showed that rCBF can be restored in the PCC, and that it is associated with transient cognitive improvement.
The findings from the present study do not necessarily contradict those of previous studies (Table 1) . Presumable causes of differences between the previous and the present findings are baseline MMSE, subgroup analysis, interval to follow-up imaging, tracers, and imaging analysis. In particular, we considered that three conditions of high baseline MMSE (mild AD), restriction to responders and short follow-up period (within 6 months) were indispensable to detect rCBF restoration in the PCC as described below. None of the previous studies fulfilled all of the three conditions. First, only mild AD patients would show the restoration of PCC rCBF, because of the vulnerability of the PCC. It has been considered that the PCC is affected early during the course of AD by accumulated findings. The vulnerability of the PCC is attributed to preferentially deposited β amyloid, 21 which occurs early during the course of AD. 22 A positron emission tomography study found that the availability of α4β2 nicotinic acetylcholine receptors in the PCC is already reduced in patients with amnestic mild cognitive impairment. 23 In this regard, patients in studies by Nakano et al., 8 Nobili et al., 9 Yoshida et al. 12 and Tateno et al.
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included a substantial number of moderate AD, accounting for the lack of positive outcomes. Second, subgroup analysis was effective. The rCBF restoration of the PCC was shown in responders, but not in non-responders. The majority of previous studies did not focus on responders, and measured rCBF together with non-responders. Just three contributions carried out analysis of responders and non-responders separately. 10, 12, 14 The patients in the study carried out by Ushijima et al. had mild AD, and MMSE scores increased to the second SPECT evaluation at 3 months. 11 The present study design was similar to theirs until this point. However, their study included six non-responders together with 11 responders, which would cause differences in the SPECT findings between this and our studies.
Third, a short interval to follow-up imaging was necessary owing to the transient nature of the recovery. We evaluated rCBF changes in PCC between baseline, and 6 and 18 months, and found that PCC rCBF increased at 6 months and decreased at 18 months in responders. These time-points were determined on the ground that the MMSE scores recovered by donepezil during the first 6 months declined thereafter. 24, 25 However, we did not exclude the possibility that other time-points within 6 months might be more suitable for detecting increased PCC rCBF. A study by Shimizu et al. identified higher rCBF in the bilateral PCC of responders than nonresponders, whereas the rCBF did not significantly increase in the PCC of responders between baseline and the endpoint. 10 Considering that the follow-up images were taken after 11 months of therapy, PCC rCBF might have increased sooner in responders. Kimura et al. also carried out subgroup analysis with follow-up SPECT after 24 months of therapy. I-IMP can show contrast particularly at the high range of CBF, and is suitable for detecting small changes in rCBF because of its higher first-pass extraction. 26 Although the image quality afforded by the use of Tc-ECD is superior as a result of the ability to administer higher doses of 99m Tc, they suffer underestimation of rCBF at high flow values. 27 Such underestimation reduces the difference between two states in PCC, which has relatively high rCBF.
The rCBF in the PCC has not previously been measured in studies using ROI analyses, because the PCC was included in a larger ROI along with other regions. For example, the pericallosal region on a 3D stereotaxic ROI template includes the upper precuneus, ACC and the PCC.
12-14 ROI should be placed on PCC properly.
Changes in MMSE and ADAS-Jcog scores significantly correlated with rCBF changes in the PCC. Previous studies have found that changes in MMSE scores and rCBF correlate in a large left frontaltemporal region, 9 the left frontal lobe and limbic lobe, 10 as well as in the parietal and temporal segment.
14 Among these three studies, the patients in a study by Shimizu et al. had mild AD, which was essentially identical to the patients described herein, and 10 The ROI of the limbic lobe in their study included the PCC, which might have contributed to the positive correlation between the changes in MMSE scores and limbic ROI. In contrast, the patients in the other two studies had more advanced AD, and their MMSE scores declined with therapy. 9, 14 The PCC in the patients in these studies might have become unresponsive to donepezil, which led to the subsequent disappearance of the correlation with MMSE scores. Thus, brain regions where changes in rCBF and MMSE correlated might vary according to clinical stage.
Changes in the PCC rCBF could be associated with connective changes in the region, considering the abundance of connections between PCC and the whole brain. The mechanisms of the reduced rCBF and metabolism in the PCC of patients with AD have been attributed to disconnection rather than focal volume loss. 28 Our finding that donepezil evoked restoration of rCBF in the PCC of responders might have relevance to restored connectivity to cholinergic nucleus.
A limitation of the present study was that we could not clarify causes of the difference between responders and non-responders. Although baseline MMSE and years of education did not significantly differ between the two groups, non-responders might have decreased cognitive reserve, considering baseline parietal non-significant hypoperfusion (Fig. S4) . The apolipoprotein Eε4 allele that might have promoted the progress of AD was not examined in the present study. Furthermore, the environment 29 and lifestyle 30 factors might also have affected the response.
In conclusion, brain perfusion SPECT identified increased rCBF in the PCC after 6 months of donepezil therapy. This increase was evident in patients with responders and high baseline MMSE. The restoration of PCC rCBF correlated with cognitive function. These present findings support our hypothesis that PCC hypoperfusion reflects integration of cholinergic dysfunction.
